Edwards Lifesciences (EW) Reports In-Line Q3 EPS

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.54, in-line with the analyst estimate of $0.54. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.

GUIDANCE:

Edwards Lifesciences sees Q4 2021 EPS of $0.53-$0.59, versus the consensus of $0.56. Edwards Lifesciences sees Q4 2021 revenue of $1.3-1.38 billion, versus the consensus of $1.41 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• KeyBanc Downgrades Kite Realty Group (KRG) to Sector Weight